Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cost-effectiveness of abatacept, rituximab, or a second TNF inhibitor after failure of a first TNF inhibitor in rheumatoid arthritis
NL-OMON26753Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of abatacept, rituximab, adalimumab, etanercept and infliximab in rheumatoid arthritis (RA) (3 arms), sponsored by Radboud University Medical Center. Primary endpoints: Mean DAS28 over follow-up, Quality-adjusted life years and 1 more. Started Jan 2009; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON26753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26753.